Emergent Biosolutions Q2 Earnings Call Highlights

Key Points

• Q2 performance exceeded expectations: Revenue reached $234 million and adjusted EBITDA rose to $97 million, driven by accelerated medical countermeasure deliveries and strong U.S. government contract activity.
• NARCAN competition is pressuring the business: Emergent recorded a $191 million non-cash impairment charge and announced restructuring measures expected to deliver approximately $40 million in annualized savings, including 90 job cuts and facility closures.
• Full-year guidance was reduced: 2026 revenue guidance fell to $645 million–$675 million, while adjusted EBITDA guidance declined to $130 million–$150 million, reflecting expected naloxone pricing and volume pressure in the second half.

Emergent Biosolutions NYSE: EBS reported second-quarter 2026 revenue and adjusted EBITDA above its prior guidance and analyst consensus, driven by accelerated medical countermeasure deliveries to U.S. government customers. The company also lowered its full-year outlook as increased competition and pricing pressure in the naloxone market are expected to weigh on sales of NARCAN.

Revenue for the second quarter totaled $234 million, above the high end of the company’s prior guidance range of $185 million. Adjusted EBITDA was $97 million, representing a 41% margin, compared with $33 million and a 23% margin in the year-earlier period. Year-to-date revenue reached $390 million, up from $363 million in the first half of 2025, while adjusted EBITDA increased to $132 million from $112 million.

Chief Executive Officer Joseph Papa said the results reflected “strong execution and acceleration” of medical countermeasure, or MCM, deliveries during the quarter. MCM revenue totaled $168 million, which Papa said was the company’s highest second-quarter MCM revenue since 2020.

Medical Countermeasures Drive First-Half Performance

Emergent said its MCM business remains a central growth driver, supported by contracts with the U.S. government and international customers. During the quarter, the company received a $52.7 million contract modification for ACAM2000 and a $64.5 million contract modification for botulism antitoxin. It secured more than 10 contract awards year to date.

International MCM sales accounted for approximately 20% of total first-half 2026 MCM revenue, according to Papa. The company cited continued engagement with U.S. and allied governments amid heightened concerns about biodefense preparedness.

Papa also said Emergent is seeking to collaborate with artificial intelligence leaders and partners to address potential bioterrorism risks and improve preparedness. He noted that the company continues to pursue programs including TEMBEXA, Ebanga and Raxibacumab. The MOSA study in Africa, which is evaluating TEMBEXA in Mpox, has enrolled more than 100 patients, with additional sites being opened by the study sponsor and partners.

During the quarter, Emergent received Saudi Food and Drug Authority approval for ACAM2000 and approval from Singapore’s Health Sciences Authority to expand ACAM2000’s label to include an Mpox indication.

NARCAN Competition Prompts Restructuring and Impairment

Management said the naloxone market changed late in the second quarter with a new 4-milligram over-the-counter nasal naloxone approval on June 16 and the anticipated August launch of a 10-milligram prescription product. The company also cited more aggressive pricing across the category.

Papa said Emergent believes NARCAN retains more than 50% of the naloxone market and remains the market leader. However, he said the company expects further price erosion as new competitors enter the market. Management expects overall naloxone unit demand to remain relatively flat.

In response, Emergent announced restructuring actions expected to generate about $40 million in annualized net savings. The measures include:

• A reduction of approximately 90 positions;
• The closure of two wet laboratories in Maryland;
• The sale of an underutilized office building for $6.4 million; and
• An exit from a central warehouse lease.

The company expects to incur approximately $11 million in costs to achieve the savings. Papa said the company will begin realizing some savings in 2026, with the full $40 million annualized run rate expected in 2027.

Chief Financial Officer Rich Lindahl said Emergent recorded a non-cash impairment charge of approximately $191 million during the second quarter related to the NARCAN asset group. The charge reflected the company’s revised assessment of expected future cash flows amid pricing and competitive developments. Lindahl said the impairment does not affect cash, liquidity, operating cash flow or adjusted EBITDA, but will reduce GAAP net income.

Emergent plans to seek growth in the commercial franchise through additional NARCAN offerings, including a carrying case, multipack configurations and wall kits.

Outlook Lowered on Commercial Revenue Pressure

Emergent lowered its full-year 2026 revenue guidance to $645 million to $675 million, from a prior range of $720 million to $760 million. The revision primarily reflects lower expected commercial revenue in the second half due to increased NARCAN competition and naloxone pricing and volume pressure.

The company maintained its view that MCM revenue would be flat to slightly down for the full year, with the first-half benefit from accelerated deliveries already reflected in reported results.

• GAAP net loss: $245 million to $225 million
• Adjusted net income: $10 million to $30 million
• Adjusted EBITDA: $130 million to $150 million, down from prior guidance of $155 million to $175 million
• Adjusted gross margin: 42% to 44%
• Third-quarter revenue: $110 million to $130 million

At June 30, Emergent had $140 million in cash and $190 million in total liquidity. Gross debt was $590 million and net debt was $450 million. Lindahl said the company collected $145 million through July from accounts receivable outstanding at quarter-end, describing the collections as normal working-capital activity rather than a securitization or financing transaction.

The company completed a term loan refinancing in April, establishing a $150 million term loan maturing in 2031. Its board also authorized a $75 million program to repurchase senior unsecured notes. During the second quarter, Emergent repurchased 1.1 million shares for approximately $9 million, bringing year-to-date share repurchases to $18 million.

About Emergent Biosolutions (NYSE:EBS)

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source